What Is Retatrutide? The Triple Agonist That Goes Further Than Ozempic

The Weight-Loss Drug Race Has a New Contender

By now you've heard of Ozempic. You've probably heard of tirzepatide, the dual agonist that outperformed semaglutide in trials and launched as Zepbound and Mounjaro. But there's a next generation compound that's been quietly generating some of the most striking weight-loss numbers ever recorded in a clinical trial. It's called retatrutide, and it doesn't just hit two targets the way tirzepatide does. It hits three.

So what is retatrutide, exactly? In plain language: it's an experimental injectable drug that activates three separate hormone receptors simultaneously — GLP-1, GIP, and glucagon — to reduce appetite, improve blood sugar, and accelerate fat burning at the same time. Phase 2 trial results published in 2023 showed participants losing an average of 24.2% of their body weight at the highest dose over 48 weeks. That's not a typo. For context, semaglutide (Ozempic/Wegovy) averages around 15%, and tirzepatide averages around 21%.

This article breaks down how retatrutide works, what makes it different from the drugs already on the market, where the clinical trials actually stand right now, and what you can do if you're interested in the GLP-1 space before retatrutide is available.

What Is Retatrutide, Really?

Retatrutide is a synthetic peptide — a small chain of amino acids — developed by Eli Lilly, the same company behind tirzepatide. Its technical designation is LY3437943, and it's currently in Phase 3 clinical trials. It has not been approved by the FDA. It is not yet available as a prescription drug.

The origin story here matters. GLP-1 receptor agonists were first developed from a compound found in the saliva of the Gila monster lizard in the 1980s. Yes, the lizard. That discovery eventually gave us exenatide, then liraglutide, then semaglutide. Each generation got more potent and longer-acting. Retatrutide is what happens when researchers ask: what if we could hit every major metabolic hormone receptor at once?

Think of your metabolism as having three separate dimmer switches for how much fat you burn and how much food you want. GLP-1 is one dimmer (appetite and insulin). GIP is another (insulin and fat storage). Glucagon is the third (energy expenditure and fat breakdown). Most drugs only touch one or two of those switches. Retatrutide, in theory, controls all three at once — and the early data suggests that matters.

How Does Retatrutide Work? The Triple Agonist Mechanism

Ready for some science that won't put you to sleep? Here's how each receptor arm of retatrutide actually functions:

GLP-1 (Glucagon-Like Peptide-1)

This is the one you already know from Ozempic. GLP-1 is a hormone your gut releases after you eat. It tells your pancreas to release insulin, tells your liver to slow down glucose production, and — crucially — tells your brain you're full. GLP-1 receptor agonists slow gastric emptying (food leaves your stomach more slowly), which is a big part of why people on semaglutide eat so much less. Retatrutide activates this receptor like its predecessors.

GIP (Glucose-Dependent Insulinotropic Polypeptide)

GIP is the second receptor tirzepatide added to the mix, and it's part of why tirzepatide outperforms semaglutide. GIP works synergistically with GLP-1 to amplify insulin release and seems to improve how fat tissue responds to insulin. There's also evidence GIP agonism reduces the nausea that GLP-1 activation can cause — which might explain why tirzepatide is often better tolerated than semaglutide despite being more potent.

Glucagon Receptor

Here's where retatrutide gets genuinely interesting — and where it departs from everything that came before it. Glucagon is typically thought of as the "counter-hormone" to insulin: when blood sugar drops, glucagon rises to release stored glucose from the liver. That sounds like it would cause problems in a weight-loss drug, and it would if you activated glucagon receptors strongly and alone. But here's the catch: at lower, calibrated levels of glucagon receptor activation, glucagon actually increases energy expenditure in the liver and promotes fat oxidation (burning fat for fuel). When that effect is layered on top of strong GLP-1 and GIP signaling — which keeps blood sugar controlled — you get a net metabolic benefit. More fat burned, without the blood sugar spike.

The glucagon component is the real differentiator. It's essentially adding a metabolic accelerant to the appetite-suppression and insulin-regulation you already get from GLP-1 and GIP. Retatrutide doesn't just make you eat less. It also makes your body burn more.

What Does the Evidence Actually Show?

The Phase 2 trial published in The New England Journal of Medicine in 2023 is the data everyone is citing. Here's what it actually found:

• 24.2% average body weight reduction at the highest dose (12 mg) over 48 weeks — the largest ever seen in a Phase 2 obesity trial at the time of publication.
• The dose-response was clear: lower doses (4 mg, 8 mg) produced 8.7% and 17.3% weight loss respectively, showing this isn't a one-size effect — it scales.
• Significant improvements in blood pressure, waist circumference, and metabolic markers across dose groups.
• Participants were adults with obesity (BMI 30-50) without type 2 diabetes, meaning these aren't the most metabolically compromised patients — the effects are in a relatively general obese population.

A separate Phase 2 trial in people with type 2 diabetes showed meaningful HbA1c reductions alongside weight loss, which matters because blood sugar control is often a co-goal for this population.

These numbers are striking. But a Phase 2 trial with a few hundred participants is not the same as Phase 3 data with thousands — and it's definitely not FDA approval. The full Phase 3 program (called TRIUMPH) is ongoing. We don't have those results yet.

Retatrutide vs. Semaglutide vs. Tirzepatide: How Do They Compare?

It's tempting to line them up and declare a winner. Here's what the data actually supports:

• Semaglutide (Ozempic/Wegovy): Single GLP-1 agonist. ~15% average weight loss in STEP trials. FDA-approved for obesity and type 2 diabetes. Well-understood safety profile over years of real-world use.
• Tirzepatide (Mounjaro/Zepbound): Dual GLP-1/GIP agonist. ~21% average weight loss in SURMOUNT trials. FDA-approved. Outperforms semaglutide head-to-head in most metrics. Better tolerability for many people than semaglutide.
• Retatrutide: Triple GLP-1/GIP/glucagon agonist. ~24% average weight loss in Phase 2. Not FDA-approved. No long-term safety data beyond 48 weeks. Phase 3 data pending.

The trend is clear: adding more receptor targets increases efficacy. But the jump from 21% (tirzepatide) to 24% (retatrutide) is more modest than the jump from 15% (semaglutide) to 21%. Whether that incremental gain is worth the additional complexity and unknown long-term effects is a real question — one that Phase 3 data needs to answer.

The Reality Check: What We Don't Know Yet

The internet wants retatrutide to be the final answer on weight loss. The research is more interesting — and more honest — than that.

First, the duration question. The longest Phase 2 data we have is 48 weeks. We don't know what happens at 2 years, 5 years. Semaglutide has years of real-world data now. Retatrutide has months of trial data in a few hundred people.

Second, the weight regain question. Every GLP-1-class drug studied so far shows significant weight regain when you stop taking it. STEP 4 data showed ~12% weight regain within a year of stopping semaglutide. There's no reason to expect retatrutide to be different, and no data yet on what stopping retatrutide looks like.

Third, the cardiovascular outcomes question. Semaglutide has the SELECT trial showing a 20% reduction in major cardiovascular events. Tirzepatide has SURMOUNT-MMO ongoing. Retatrutide has no cardiovascular outcomes trial data yet. For anyone considering a GLP-1-class drug partly for heart health reasons — and they should be — that data gap matters.

Finally: retatrutide is not available. It has not been approved by any regulatory agency. Anyone claiming to sell it right now is selling something that has not passed Phase 3 trials and has no established safety or manufacturing standard. That's not a bureaucratic complaint — that's a patient safety fact.

Who Is Retatrutide Actually Right For (When It Arrives)?

Based on the Phase 2 trial design and the mechanism, retatrutide will likely be most relevant for people who:

• Have a BMI of 30 or above, or BMI 27+ with at least one weight-related health condition (the likely label criteria, based on how GLP-1 drugs are typically approved)
• Have not achieved sufficient results on semaglutide or tirzepatide — or want to start at the top of the efficacy ladder when it's available
• Have metabolic comorbidities where the additional glucagon component might offer extra benefit: non-alcoholic fatty liver disease (NAFLD), insulin resistance, elevated triglycerides
• Are willing to be on a medication indefinitely, understanding that stopping will likely mean weight regain

It's probably not the right starting point for someone with mild overweight, or someone who hasn't tried lifestyle intervention seriously. And for anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome — the contraindication that applies to all GLP-1 class drugs — it would be off the table regardless.

Risks and Side Effects: What to Expect

Based on Phase 2 data, retatrutide's side effect profile looks similar to other GLP-1 class drugs, with a few notes:

• Nausea, vomiting, diarrhea: The most common adverse events, occurring in a significant minority of participants, mostly during dose escalation. Usually transient.
• Decreased appetite: This is a feature and a side effect simultaneously — some people find it disruptive to their relationship with food and eating.
• Injection site reactions: Mild, as with other injectables.
• Heart rate increase: A small elevation in resting heart rate has been noted with retatrutide, consistent with what's seen in other GLP-1 agonists. Worth monitoring.
• Gallbladder events: Rapid weight loss from any cause increases gallstone risk. GLP-1 class drugs have a known association here. Monitoring matters.
• Unknown unknowns: With only 48 weeks of data, there are side effects that simply haven't shown up yet. This is the honest truth with any Phase 2 compound.

The right answer to all of this is clinical supervision — not higher doses, not guesswork, and definitely not a telehealth script with no follow-up.

What You Can Do Right Now: The Healthspan Approach to GLP-1 Care

Retatrutide isn't available yet. But the GLP-1 landscape already has highly effective, FDA-approved options — and the evidence suggests that a clinically supervised protocol is what separates meaningful, lasting results from a frustrating experience of side effects and weight regain.

At Healthspan, GLP-1 Longevity Care is a medically supervised program designed for people who want the real clinical protocol, not just a prescription. It includes a comprehensive intake consultation to evaluate whether you're a candidate, baseline labs to understand your metabolic starting point, and physician oversight throughout — including dose titration, side effect management, and monitoring of the metrics that matter (blood sugar, lipids, liver markers, heart rate). The goal isn't just weight loss. It's improving the metabolic picture that drives long-term health and longevity.

If you're interested in tirzepatide specifically — currently the most potent FDA-approved option in this class — Zepbound® with Ongoing Care is also available through Healthspan, with the same clinical oversight model. And for those who want a complete view of their metabolic health before starting any GLP-1 protocol, the Longevity Pro Panel provides a comprehensive baseline across all the biomarkers that matter.

If retatrutide interests you, the smartest move right now is to get your metabolic baseline established, understand what's actually driving your weight and metabolic health, and work with clinicians who will be tracking the retatrutide data as it comes in. That's not a delay — that's the right starting point. Book a consultation with Healthspan to talk through where you stand and which protocol makes sense for you today.

Frequently Asked Questions About Retatrutide

What is retatrutide and how is it different from Ozempic?

Retatrutide is an experimental injectable drug developed by Eli Lilly that activates three hormone receptors simultaneously: GLP-1, GIP, and glucagon. Ozempic (semaglutide) activates only GLP-1. The triple mechanism gives retatrutide a more powerful effect on both appetite suppression and fat burning, with Phase 2 trials showing about 24% average body weight loss versus roughly 15% for semaglutide. However, retatrutide is not yet FDA-approved, while Ozempic is.

Is retatrutide available to buy or prescribe right now?

No. As of 2025, retatrutide has completed Phase 2 trials and is in Phase 3 (the TRIUMPH program), but it has not been approved by the FDA or any major regulatory agency. It is not legally available for prescription. Anyone selling "retatrutide" currently is not selling an approved, standardized pharmaceutical product. Approval is expected to be several years away at minimum.

How much weight loss does retatrutide cause?

In its Phase 2 trial published in the New England Journal of Medicine in 2023, participants taking the highest dose (12 mg) lost an average of 24.2% of their body weight over 48 weeks. Lower doses produced 8.7% and 17.3% weight loss. These are the largest numbers ever recorded in a Phase 2 obesity trial, but Phase 3 data — which tests larger populations — is still pending.

What are the side effects of retatrutide?

Based on Phase 2 data, the most common side effects are nausea, vomiting, and diarrhea — especially during dose escalation — which is consistent with other GLP-1 class drugs. A small increase in resting heart rate has also been observed. Because only 48 weeks of trial data exist, the long-term side effect profile is not yet fully established. Gallbladder events are a known risk with rapid weight loss from any GLP-1-class medication.

How does retatrutide compare to tirzepatide (Zepbound/Mounjaro)?

Tirzepatide is a dual GLP-1/GIP agonist that averages about 21% weight loss and is FDA-approved. Retatrutide adds a third receptor target (glucagon), which appears to increase weight loss to around 24% in Phase 2. The incremental gain over tirzepatide is real but more modest than the jump from semaglutide to tirzepatide. Tirzepatide has full FDA approval, years of safety data, and established cardiovascular outcome trials in progress. Retatrutide has neither yet.

What does the glucagon receptor activation in retatrutide actually do?

Glucagon is typically the "counter-hormone" to insulin — it raises blood sugar when levels drop. But at lower, calibrated activation levels alongside strong GLP-1 and GIP signaling, glucagon receptor activation increases energy expenditure in the liver and promotes fat oxidation (fat burning). The GLP-1 component keeps blood sugar under control, while the glucagon component essentially turns up your metabolic rate. This combination is what makes retatrutide's weight-loss numbers higher than its predecessors.

What should I do if I'm interested in retatrutide but it's not available yet?

The best move is to get your metabolic baseline established now. Understanding your current blood sugar, insulin sensitivity, lipid profile, and other metabolic markers means you'll be ready to have an informed conversation when retatrutide becomes available — and may identify FDA-approved options like tirzepatide that are already appropriate for you. A clinically supervised GLP-1 program through a longevity clinic is the right starting point.